Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bac-in-a-Box + prevotella melaninogenica
- Development stage
- Preclinical
- Lead developer
- Austrianova
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Cell Therapies, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bac-in-a-Box + prevotella melaninogenica is an experimental bacterial cell therapy being developed by Austrianova in collaboration with San Raffaele University for the treatment of multiple myeloma. The therapy consists of *Prevotella melaninogenica*, a commensal bacterium of the human gastrointestinal microbiota, encapsulated in cellulose beads using Austrianova's patented Bac-in-a-Box technology. This encapsulation is designed to protect the bacteria from stomach acid and allow for room temperature storage while maintaining viability. Preclinical studies conducted by Dr. Matteo Bellone's group at San Raffaele have shown that *P. melaninogenica* can protect against the progression of asymptomatic smoldering multiple myeloma to the aggressive, active form of the disease. The program is currently in the preclinical stage of development.
- Brand names
- Bac-in-a-Box
- Other names
- Bac-in-a-Box Prevotella melaninogenicaPrevotella melaninogenica (Bac-in-a-Box)
Beyond the preview
Go deeper on Bac-in-a-Box + prevotella melaninogenica.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bac-in-a-Box + prevotella melaninogenica.